WO2010132622A3 - Anticd20-cpg conjugates and methods of treating b cell malignancies - Google Patents

Anticd20-cpg conjugates and methods of treating b cell malignancies Download PDF

Info

Publication number
WO2010132622A3
WO2010132622A3 PCT/US2010/034628 US2010034628W WO2010132622A3 WO 2010132622 A3 WO2010132622 A3 WO 2010132622A3 US 2010034628 W US2010034628 W US 2010034628W WO 2010132622 A3 WO2010132622 A3 WO 2010132622A3
Authority
WO
WIPO (PCT)
Prior art keywords
anticd20
methods
treating
cell malignancies
cpg conjugates
Prior art date
Application number
PCT/US2010/034628
Other languages
French (fr)
Other versions
WO2010132622A2 (en
Inventor
John M. Timmerman
Kamran Kafi Tehrani
David J. Betting
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of WO2010132622A2 publication Critical patent/WO2010132622A2/en
Publication of WO2010132622A3 publication Critical patent/WO2010132622A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Disclosed herein are antiCD20-CpG conjugates and methods of using thereof to treat or inhibit B cell malignancies.
PCT/US2010/034628 2009-05-14 2010-05-13 Anticd20-cpg conjugates and methods of treating b cell malignancies WO2010132622A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17836609P 2009-05-14 2009-05-14
US61/178,366 2009-05-14

Publications (2)

Publication Number Publication Date
WO2010132622A2 WO2010132622A2 (en) 2010-11-18
WO2010132622A3 true WO2010132622A3 (en) 2011-03-03

Family

ID=43085575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/034628 WO2010132622A2 (en) 2009-05-14 2010-05-13 Anticd20-cpg conjugates and methods of treating b cell malignancies

Country Status (1)

Country Link
WO (1) WO2010132622A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7062298B2 (en) 2012-07-18 2022-05-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Compounds for targeted immunotherapy

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015205756A1 (en) 2014-01-10 2016-07-21 Birdie Biopharmaceuticals Inc. Compounds and compositions for treating EGFR expressing tumors
US20160340439A1 (en) * 2014-01-22 2016-11-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy
WO2016064899A1 (en) * 2014-10-21 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
CN106943597A (en) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 Anti-EGFR for treating tumour is combined
KR20230149857A (en) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
JP2019524787A (en) 2016-08-03 2019-09-05 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド TLR9 targeted therapeutics
CA3058966A1 (en) 2017-04-14 2018-10-18 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
CN108794467A (en) 2017-04-27 2018-11-13 博笛生物科技有限公司 2- amino-quinoline derivatives
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
US20050191342A1 (en) * 2003-10-11 2005-09-01 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026801A1 (en) * 2000-06-22 2003-02-06 George Weiner Methods for enhancing antibody-induced cell lysis and treating cancer
US20050191342A1 (en) * 2003-10-11 2005-09-01 Inex Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRIEDBERG,J.W. ET AL.: "Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.", BLOOD., vol. 105, no. 2, 9 September 2004 (2004-09-09), pages 489 - 495 *
JAHRSDORFER, B. ET AL.: "CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.", J. LEUKOC. BIOL., vol. 69, no. 1, January 2001 (2001-01-01), pages 81 - 88, XP001095223 *
KRISHNAMACHARI, Y. ET AL.: "Innovative strategies for co-delivering antigens and CpG oligonucleotides.", ADV. DRUG DELIV. REV., vol. 61, no. 3, 19 January 2009 (2009-01-19), pages 205 - 217 *
TIMMERMAN, J. ET AL.: "In vivo activity of rituximab-CpG oligodeoxynucleotide conjugate against rituximab-resistant human CD20+ B-cell lymphoma.", JOURNAL OF CLINICAL ONCOLOGY, ASCO MEETING PROCEEDINGS (POST-MEETING ED.), vol. 27, no. 15S, 8 June 2009 (2009-06-08) *
YANG, L. ET AL.: "Functional analysis of a dominant negative mutation of interferon regulatory factor 5.", PLOS ONE., vol. 4, no. 5, 11 May 2009 (2009-05-11), pages E5500 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7062298B2 (en) 2012-07-18 2022-05-06 バーディー バイオファーマシューティカルズ インコーポレイテッド Compounds for targeted immunotherapy

Also Published As

Publication number Publication date
WO2010132622A2 (en) 2010-11-18

Similar Documents

Publication Publication Date Title
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
MX344786B (en) Compositions and methods for treating gaucher disease.
IL218987A0 (en) Methods and compositions for treating cancer
MX2011008221A (en) Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor.
IL215581A0 (en) Engineered mesenchymal stem cells and method of using same to treat tumors
WO2009111676A3 (en) Boron-containing small molecules as anti-inflammatory agents
EP2499486A4 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EP2068798A4 (en) Methods, compositions and apparatuses to treat wounds with pressures altered from atmospheric
WO2009114703A3 (en) Combination therapy for the treatment of cancer
WO2011020107A3 (en) Compositions and methods for detection and treatment of breast cancer
WO2009095261A3 (en) Vaccine compositions
EP2419136A4 (en) Compositions and methods for treating cancer
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
IL214349A0 (en) Compositions and methods for the treatment of cancer
EP2437738A4 (en) Methods and compositions for the treatment of cancer
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2011130697A3 (en) Tissue targeting
PL2446276T3 (en) Methods for determining the oncogenic condition of cell, uses thereof, and methods for treating cancer
WO2010127197A3 (en) Method and composition for treating diabetic ketoacidosis
EP2424527B8 (en) Mast cell stabilizers to prevent or treat laminitis
IL214757A0 (en) Compositions and methods to prevent and/or treat cancer with pa-card
WO2010138171A9 (en) Methods for cancer treatment using stem cells
AU2010298020A8 (en) Combination
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
EP2411031A4 (en) Methods and compositions for the treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10775509

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10775509

Country of ref document: EP

Kind code of ref document: A2